| Title | Author(s) | Year | View Count |  | Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir | Gish, RG; Chang, TT; Lai, CL; de Man, RA; Gadano, A; Llamoso, C; Tang, H | 2013 | 1 |
| Decline in hepatitis B surface antigen levels with entecavir treatment in HBeAg-positive nucleoside naive chronic Hepatitis B patients-results from phase III study ETV-022 | Gish, R; Chang, TT; Lai, CL; De Man, RA; Gadano, A; Yu, S; Llamoso, C; Tang, H | 2012 | 59 |
| Long-term entecavir treatment for up to 5 years in Asians with HBEAG-positive nucleos(T)ide naïve chronic hepatitis B: results from ETV-022 and -901 | Pan, C; Tong, MJ; Kowdley, KV; Hu, KQ; Chang, TT; Lai, CL; Yoon, SK; Lee, SS; Cohen, DS; Tang, H; Tsai, N | 2010 | 126 |
 | Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B | Gish, RG; Chang, TT; Lai, CL; De Man, R; Gadano, A; Poordad, F; Yang, J; BrettSmith, H; Tamez, R | 2010 | 320 |
| Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B | Chang, TT; Liaw, YF; Wu, SS; Schiff, E; Han, KH; Lai, CL; Safadi, R; Lee, SS; Halota, W; Goodman, Z; Chi, YC; Zhang, H; Hindes, R; Iloeje, U; Beebe, S; Kreter, B | 2010 | 90 |
| Entecavir treatment for up to 5 years in patients with hepatitis b e antigen-positive chronic hepatitis B | Chang, TT; Lai, CL; Yoon, SK; Lee, SS; Coelho, HSM; Carrilho, FJ; Poordad, F; Halota, W; Horsmans, Y; Tsai, N; Zhang, H; Tenney, DJ; Tamez, R; Iloeje, U | 2010 | 116 |
| Efficacy of entecavir in chronic hepatitis b patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage | Wu, IC; Lai, CL; Bui Han, SH; Han, KH; Gordon, SC; Chao, YC; Tan, CK; Sievert, W; Tanwandee, T; Xu, D; Neo, BL; Chang, TT | 2010 | 56 |
| Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy | Shouval, D; Lai, CL; Chang, TT; Cheinquer, H; Martin, P; Carosi, G; Han, S; Kaymakoglu, S; Tamez, R; Yang, J; Tenney, D; BrettSmith, H | 2009 | 75 |
| Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (-) chronic hepatitis B: results from studies ETV-022, -027 and -901. | Liaw, YF; Chang, TT; Wu, SS; Schiff, ER; Han, KH; Lai, CL; Safadi, R; Lee, SS; Halota, W; Goodman, ZD; Zhang, H; Hindes, R; Hoeje, U; Beebe, S; Kreter, B | 2008 | 200 |
| Three years of entecavir (etv) re-treatment of HBeAg(-) etv patients who previously discontinued ETV treatment: results from study ETV-901 | Shouval, D; Lai, CL; Chang, TT; Gadano, A; Wu, SS; Halota, W; Sievert, W; Tsai, NCSC; Zhang, H; Iloeje, U | 2008 | 167 |
| Efficacy of entecavir in nucleoside-naefve patients with mildly elevated ALT | Gordon, SC; Han, SH; Chang, TT; Lai, CL; Han, KH; Chao, YC; Tan, CK; Sievert, W; Tanwandee, T; Neo, BL | 2008 | 104 |
 | Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B | Lai, CL; Shouval, D; Lok, AS; Chang, TT; Cheinquer, H; Goodman, Z; DeHertogh, D; Wilber, R; Zink, RC; Cross, A; Colonno, R; Fernandes, L | 2006 | 420 |
| Continued Virologic Improvement Through 96 Weeks of Entecavir Treatment in HBeAg(-) Chronic Hepatitis B Patients (Study ETV-027) | Poordad, F; Dieterich, DT; Min, AD; Shouval, D; Lai, CL; Cheinquer, H; Chang, TT; Zink, R; Zhu, J; Brett-Smith, H | 2006 | 86 |
| Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(？) chronic hepatitis B patients (study ETV-027) | Shouval, D; Akarca, US; Hatzis, G; Kitis, G; Lai, CL; Cheinquer, H; Chang, TT; Zink, R; Zhu, J; Brett-Smith, H | 2006 | 111 |
| Hepatitis B Surface Antigen Loss in Antiviral-treated Patients with HBeAg(+) Chronic Hepatits B (CHB) Infection: Observations from Antiviral-naive Patients Treated with Entecavir (ETV) or lamivudine (LVD) | Gish, R; Chang, TT; Lai, CL; de Man, R; Gadano, A; Poordad, F; Zhu, J; Yang, J; Brett-Smith, H | 2006 | 102 |
| Hepatitis B virus with primary resistance to adefovir [11] | Chang, TT; Lai, CL | 2006 | 143 |
| Four years of lamivudine treatment in Chinese patients with chronic hepatitis B | Chang, TT; Lai, CL; Chien, RN; Guan, R; Lim, SG; Lee, CM; Ng, KY; Nicholls, GJ; Dent, JC; Leung, NWY | 2004 | 137 |
| Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy | Leung, NWY; Lai, CL; Chang, TT; Guan, R; Lee, CM; Ng, KY; Lim, SG; Wu, PC; Dent, JC; Edmundson, S; Condreay, LD; Chien, RN | 2001 | 70 |
| Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatiits B e antigen seroconversion rate: results after 3 years of therapy | Leung, NW; Lai, CL; Chang, TT; Guan, R; Lee, CM; Ng, KY; Lim, SG; Wu, PC; Dent, JC; Edmundson, S; Condreay, LD; Chien, RN | 2001 | 119 |
| Effects of extended lamivudine therapy in asian patients with chronic hepatitis B | Liaw, YF; Leung, NWY; Chang, TT; Guan, R; Tai, DI; Ng, KY; Chien, RN; Dent, J; Roman, L; Edmundson, S; Lai, CL | 2000 | 73 |
|
